Posted by Michael Wonder on 27 Nov 2023
EMA accepts Valneva’s Chikungunya vaccine marketing authorisation application for accelerated assessment
27 November 2023 - Valneva today announced that the EMA has performed a technical validation of the marketing authorisation application for Valneva’s single shot chikungunya vaccine candidate VLA1553 and has determined that all essential regulatory elements required for scientific assessment were included in the application.
The marketing authorisation application was granted accelerated assessment last month by EMA’s CHMP based on the vaccine candidate’s “major interest for public health and therapeutic innovation”.
